At the Alliance for Clinical Trials in Oncology, our media relations efforts are designed to alert the public about the vital work happening across our network. When we share stories about groundbreaking clinical trials, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible. These media features serve a crucial…
The Alliance for Clinical Trials in Oncology is currently seeking nominations for two prestigious lectureships: the 2026 Jimmie C. Holland Lecture (Fall 2026 Meeting) and the 2027 Charles G. Moertel Lecture (Spring 2027 Meeting): 1. The 2026 Jimmie C. Holland Lecturer About the Award: Jimmie C. Holland, MD, founded the field of psycho-oncology, a discipline…
Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment. This marks a…
The Alliance for Clinical Trials in Oncology has launched a new national study to see if an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Alliance A082302 aims to enroll 336 participants in this phase III trial specifically focusing on patients with stage I non-small cell lung cancer. Currently, after…
The Alliance for Clinical Trials in Oncology has honored Electra Paskett, PhD, FACE, FAACR, FASCO, as the 2026 Charles G. Moertel Lecturer. Dr. Paskett is the Marion N. Rowley Professor of Cancer Research and Director at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, as well as the Director and Principal Investigator…
The Alliance for Clinical Trials in Oncology thrives on the dedication, vision, and expertise of its leadership team. We express our deep gratitude to the outgoing committee chairs whose years of tireless service have fundamentally shaped our research portfolio, advanced clinical trials, and mentored the next generation of investigators while profoundly impacting the lives of…
A new randomized Alliance Foundation Trials (AFT) clinical study found that men with advanced prostate cancer taking the hormone therapy medication darolutamide had less cognitive decline compared to men taking enzalutamide. According to results from the ARACOG (AFT-47) phase II trial, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2026,…
Categories
Alliance Committee
Browse by Year